Premature Ventricular Contractions (pvcs) Induced by Administration of Cilostazol after Myocardial Infarction

Cilostazol is a phosphodiesterase III inhibitor, which was approved by FDA (food and drug administration) for intermittent claudication in 1999. What made it known to cardiologists is the Cilostazol for Restenosis Trial (CREST), in which cilostazol was shown to significantly lower binary restenosis rate. Here we reported one case of acquired premature… CONTINUE READING